AHAbraham Haimed

Abraham Haimed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abraham Haimed has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Roadmap for Developing and Implementing Duffy Null-Specific Reference Intervals

    by Lauren E Merz, Vivian Y Chang, Warren B Fingrut, Lucy A Godley, Abraham Haimed, Chibuzo Ilonze, Zhen Wei Mei, Alexa J. Siddon, Amy Soni, Samuel R Wilson, et al.

    The Duffy null variant is found in 10% of the United States population, and results in distinct absolute neutrophil counts (ANC) and white blood cell count (WBC) RIs. Investigators from twenty-three institutions completed a collaborative assessment of ANC and WBC in healthy Duffy-null pediatric and adult participants. This report summarizes a roadmap for developing and implementing Duffy-null RIs and infrastructure. Through consensus, we identified the following key themes: 1) Identifying Stakeholders and Funding, 2) Collecting Samples, 3) Testing for Duffy Status, 4) Implementing Duffy-Specific Policies and Tools, and 5) Educating Providers and Duffy-null individuals. Across themes, we outline challenges and opportunities relevant to the development and implementation of Duffy-null infrastructure. We provide examples from community and academic practice settings as well as sites with geographic, size, funding, and population diversity. This roadmap will support healthcare systems, hospitals, and laboratories in developing and implementing Duffy-specific infrastructure.

  • Open Access

    Establishing Absolute Neutrophil Count and White Blood Cell Count Reference Intervals for the Duffy Null Population

    by Lauren E Merz, Aliza Fink, Hyojeong Han, Cyril Jacquot, Abraham Haimed, Stella T. Chou, Alexis A. Thompson, Vivian Y Chang, Zhen Wei Mei, J. Mark Sloan, et al.

    Most reference intervals (RI) for absolute neutrophil count (ANC) and white blood cell count (WBC) in the United States (US) are not representative of people with the Duffy null phenotype (10% of the US population), which leads to misdiagnoses and inequity in care. We aimed to verify the adult Duffy null ANC RI and develop WBC and ANC RIs for pediatrics. 1,412 healthy Duffy null participants from 23 sites were included. All sites agreed on eligibility criteria. Otherwise, this was a pragmatic design with site-specific variation in collection approach. ANC and WBC were stratified into 5 age categories: 6 months-2 years, 3-6 years, 7-12 years, 13-17 years, and 18+ years. RI were calculated by Clinical and Laboratory Standards Institute guidelines. Duffy null-specific ANC RI were 0.53-4.50×109/L (6 months-2 years, n=184), 0.78-4.67×109/L (3-6 years, n=160), 0.87-5.34×109/L (7-12 years, n=190), 0.90-4.89×109/L (13-17 years, n=216), and 1.03-7.30×109/L (18+ years, n=662). 25% of adults had ANC <2.00×109/L and 24-53% of children had ANC <1.50×109/L. Sensitivity analyses did not show any significant differences in ANC RI when accounting for blood draw type, setting, collection site, hematology analyzer, or hemoglobin and platelet counts. This study provides the first report of Duffy null-specific pediatric ANC and WBC RI, as well as a large-scale verification of adult Duffy null-specific ANC and WBC RI. Adoption of Duffy null-specific RIs is necessary for the accurate interpretation of laboratory values that will support appropriate and equitable medical decision-making.

  • Peri-operative Anticoagulation Strategies, Bleeding and Thrombotic Complications in Pediatric Patients Undergoing Intervention for Congenital Portosystemic Shunts

    by Abraham Haimed, Katherine A. Brandt, Sherif Badawy, Caroline P. Lemoine, Rukhmi Bhat, Riccardo Superina

  • Open Access

    Intravenous fluid therapy and hospital outcomes for vaso‐occlusive episodes in children, adolescents, and young adults with sickle cell disease

    by Abraham Haimed, Rebecca Weiss, Soyang Kwon, Rukhmi Bhat, Sherif M. Badawy

    Background: While intravenous fluid (IVF) therapy in patients with sickle cell disease (SCD) admitted for a vaso‐occlusive episode (VOE) can help reduce red blood cell sickling, clinical practice varies across institutions. We examined the relationship between IVF therapy and hospital length of stay (HLOS), as well as adverse events, such as acute chest syndrome (ACS), pediatric intensive care unit (PICU) transfer, and 28‐day re‐admission.Methods: This is a single‐center retrospective analysis of SCD VOE hospitalizations between January 2015 and April 2020. Patients with SCD, age 0–30, with consecutive hospitalizations for VOE were included. For the first 3 days of each admission, an “IVF ratio” was calculated by dividing actual IVF rate administered by weight‐based maintenance IVF (mIVF) rate.Results: A total of 617 hospitalizations for 161 patients were included. Mean HLOS was 5.7 days, (SD 3.9), and mean IVF volume over the first 3 days of admission was 139.6 mL/kg/day (SD 57.8). Multivariate analysis showed that for each additional 0.5 times the mIVF rate, HLOS increased by 0.53 day (p < .001; 95% confidence interval [CI]: 0.609–0.989), but there was no significant association between IVF therapy and adverse events. History of chronic pain was associated with increased odds of re‐admission (OR 6.4; 95% CI: 3.93–10.52).Conclusions: Despite the theoretical potential for IVF therapy to slow down the sickling process, our findings suggest that increased IVF therapy was associated with prolonged HLOS, which places a burden on patients, families, and the health system.


  • Open Access

    Intravenous Fluid Therapy and Hospital Outcomes for Vaso-Occlusive Episodes in Children, Adolescents, and Young Adults with Sickle Cell Disease

    by Abraham Haimed, Rebecca Weiss, Soyang Kwon, Rukhmi Bhat, Sherif Badawy

    Background: While intravenous fluid (IVF) therapy in patients with sickle cell disease (SCD) admitted for a vaso-occlusive episodes (VOE) can help reduce red blood cell sickling, clinical practice varies across institutions. We examined the relationship between IVF therapy and hospital length of stay (HLOS), as well as adverse events, such as acute chest syndrome (ACS), pediatric intensive care unit (PICU) transfer and 28-day readmission. Methods: This is a single-center retrospective analysis of SCD VOE hospitalizations between January 2015 and April 2020. Patients with SCD, age 0-30, with consecutive hospitalizations for VOE were included. For the first 3 days of each admission, an “IVF ratio” was calculated by dividing actual IVF rate administered by weight-based maintenance IVF (mIVF) rate. Results: A total of 617 hospitalizations for 161 patients were included. Mean HLOS was 5.7 days, (SD 3.9), and mean IVF volume over the first 3 days of admission was 139.6 ml/kg/day (SD 57.8). Multivariate analysis showed that for each additional 0.5 times the mIVF rate, HLOS increased by 0.53 days (PConclusions: Despite the theoretical potential for IVF therapy to slow down the sickling process, our findings suggest that increased IVF therapy was associated with prolonged HLOS, which places a burden on patients, families, and the health system.